Alzheimer's: the therapeutic effectiveness of cannabis
Alzheimer's Donation
Donate Online Now
.
Cannabis-derived medicines may one day be used in the treatment of Alzheimer's disease which affects 417,000 people in the UK.
Professor Raphael Mechoulam of the Hebrew University of Jerusalem, Israel, will present new findings to a group of international experts at a Cannabinoids Medicines Symposium to be held at the Royal Pharmaceutical Society of Great Britain (RPSGB) in London on Monday, 10 March. The research, still at an early stage, indicates that memory loss, the main symptom of Alzheimer's, can be slowed down significantly in mice by some of the chemicals present in cannabis. The next step will be to initiate human trials to see if the same effect can be achieved on the human brain.
The research is promising for the millions of suffers of the disease and their carers. Alzheimer's disease is the commonest form of dementia, which affects an estimated 24.3 million people worldwide.
It is ten years since the RPSGB launched its protocols to demonstrate the therapeutic effectiveness of cannabis. These protocols led to the Government funded UK trials that looked at the medicinal benefits of cannabis for patients with multiple sclerosis and in the treatment of severe pain. Cannabis-derived medicines have subsequently entered the market and are currently available to patients in Canada.
Professor Tony Moffat, who is chairing the Symposium on Monday said: "We have come a long way in ten years and there is still a lot of research ground to cover. There is currently considerable interest in the medical benefits of cannabis and related compounds for a range of conditions including arthritis, multiple sclerosis and neurological pain. Although recent press coverage has focused on the abuses associated with the plant, cannabis-derived medications may offer novel opportunities in drug discovery." ttp://www.medicalnewstoday.com
Professor Raphael Mechoulam of the Hebrew University of Jerusalem, Israel, will present new findings to a group of international experts at a Cannabinoids Medicines Symposium to be held at the Royal Pharmaceutical Society of Great Britain (RPSGB) in London on Monday, 10 March. The research, still at an early stage, indicates that memory loss, the main symptom of Alzheimer's, can be slowed down significantly in mice by some of the chemicals present in cannabis. The next step will be to initiate human trials to see if the same effect can be achieved on the human brain.
The research is promising for the millions of suffers of the disease and their carers. Alzheimer's disease is the commonest form of dementia, which affects an estimated 24.3 million people worldwide.
It is ten years since the RPSGB launched its protocols to demonstrate the therapeutic effectiveness of cannabis. These protocols led to the Government funded UK trials that looked at the medicinal benefits of cannabis for patients with multiple sclerosis and in the treatment of severe pain. Cannabis-derived medicines have subsequently entered the market and are currently available to patients in Canada.
Professor Tony Moffat, who is chairing the Symposium on Monday said: "We have come a long way in ten years and there is still a lot of research ground to cover. There is currently considerable interest in the medical benefits of cannabis and related compounds for a range of conditions including arthritis, multiple sclerosis and neurological pain. Although recent press coverage has focused on the abuses associated with the plant, cannabis-derived medications may offer novel opportunities in drug discovery." ttp://www.medicalnewstoday.com
Proteins isolated from the humble potato may be biologically active and capable of reducing blood pressure, as well as having antioxidant activity, Finnish researchers report. http://www.nutraingredients.com
Posted YVN
posted by Valery Yermalitsky at
7:42 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home